We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Mia
Rodziewicz
mia.rodziewicz@manchester.ac.uk
Dr
Mia
Rodziewicz
mia.rodziewicz@manchester.ac.uk
Systemic connective tissue disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Systemic lupus erythematous (SLE) or lupus is an incurable disease of the immune system that most commonly affects women of childbearing age. The medications used to treat lupus have not been well studied in lupus and can cause significant side effects. The variety of symptoms and the relative rarity of the disease make it difficult to study and because of this, there has only been one drug licensed to treat it in the past 50 years. The aim of this project is to find markers in the blood and urine to help predict which patients will not respond to standard treatments and those who are more likely to suffer side effects. This will help guide the choice of the best treatments for patients and the development of new drugs in in the future.
This study will take place at Manchester Foundation Trust rheumatology departments (Manchester Royal Infirmary and Wythenshawe Hospital) and aims to recruit 40 lupus patients who require a change in their medication due to active disease. Clinical information relating to lupus activity will be regularly recorded and participants will be invited to complete questionnaires about quality of life, mental wellbeing and attitudes to treatment, at their usual clinic appointments. Patients will be followed for up to 3 years. Additional blood and urine samples will be taken only at times when samples are needed for patients' usual care. The extra samples will be tested for to look for novel markers of how disease activity changes over time.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patients unwilling or unable to provide consent Patients older than 80 or younger than 16 years
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Manchester and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49024
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
